O	0	12	Locoregional
O	13	23	recurrence
O	24	29	after
B-intervention	30	41	doxorubicin
I-intervention	41	42	-
I-intervention	42	47	based
I-intervention	48	60	chemotherapy
O	61	64	and
B-intervention	65	79	postmastectomy
O	79	80	:
O	81	93	Implications
O	94	97	for
B-eligibility	98	104	breast
I-eligibility	105	111	cancer
I-eligibility	112	120	patients
I-eligibility	121	125	with
I-eligibility	126	131	early
I-eligibility	131	132	-
I-eligibility	132	137	stage
I-eligibility	138	145	disease
O	146	149	and
O	150	160	predictors
O	161	164	for
O	165	175	recurrence
O	176	181	after
O	182	196	postmastectomy
O	197	206	radiation
O	206	207	.

O	208	210	To
O	211	218	compare
O	219	224	rates
O	225	227	of
O	228	240	locoregional
O	241	251	recurrence
O	252	253	(
O	253	256	LRR
O	256	257	)
O	258	263	after
O	264	274	mastectomy
O	274	275	,
O	276	287	doxorubicin
O	287	288	-
O	288	293	based
O	294	306	chemotherapy
O	306	307	,
O	308	311	and
O	312	321	radiation
O	322	326	with
O	327	332	those
O	333	335	of
O	336	344	patients
O	345	354	receiving
B-control	355	365	mastectomy
I-control	366	369	and
I-control	370	381	doxorubicin
I-control	381	382	-
I-control	382	387	based
I-control	388	400	chemotherapy
I-control	401	408	without
I-control	409	418	radiation
O	419	422	and
O	423	425	to
O	426	435	determine
O	436	446	predictors
O	447	449	of
O	450	453	LRR
O	454	459	after
O	460	474	postmastectomy
O	475	484	radiation
O	484	485	.

O	486	492	Kaplan
O	492	493	-
O	493	498	Meier
O	499	506	freedom
O	506	507	-
O	507	511	from
O	511	512	-
O	512	515	LRR
O	516	521	rates
O	522	526	were
O	527	537	calculated
O	538	541	for
B-total-participants	542	545	470
O	546	554	patients
O	555	562	treated
O	563	567	with
O	568	578	mastectomy
O	578	579	,
O	580	591	doxorubicin
O	591	592	-
O	592	597	based
O	598	610	chemotherapy
O	610	611	,
O	612	615	and
O	616	630	postmastectomy
O	631	640	radiation
O	641	643	in
O	644	648	five
O	649	655	single
O	655	656	-
O	656	667	institution
O	668	676	clinical
O	677	683	trials
O	683	684	.

O	685	688	The
O	689	692	LRR
O	693	698	rates
O	699	701	in
O	702	707	these
O	708	716	patients
O	717	721	were
O	722	730	compared
O	731	733	to
O	734	744	previously
O	745	753	reported
O	754	759	rates
O	760	762	in
O	763	767	1031
O	768	776	patients
O	777	784	treated
O	785	792	without
O	793	802	radiation
O	803	805	in
O	806	809	the
O	810	814	same
O	815	821	trials
O	821	822	.

O	823	829	Median
O	830	836	follow
O	836	837	-
O	837	839	up
O	840	843	was
O	844	846	14
O	847	852	years
O	852	853	.

O	854	864	Irradiated
O	865	873	patients
O	874	877	had
O	878	891	significantly
O	892	896	less
O	897	906	favorable
B-outcome	907	917	prognostic
I-outcome	918	925	factors
I-outcome	926	929	for
I-outcome	930	933	LRR
O	934	938	than
O	939	942	did
O	943	955	unirradiated
O	956	964	patients
O	964	965	.

O	966	973	Despite
O	974	978	this
O	978	979	,
O	980	982	in
O	983	986	all
O	987	994	subsets
O	995	997	of
O	998	1002	node
O	1002	1003	-
O	1003	1011	positive
O	1012	1020	patients
O	1020	1021	,
O	1022	1036	postmastectomy
O	1037	1046	radiation
O	1047	1050	led
O	1051	1053	to
O	1054	1059	lower
B-outcome	1060	1065	rates
I-outcome	1066	1068	of
I-outcome	1069	1072	LRR
O	1072	1073	.

O	1074	1078	This
O	1079	1087	included
O	1088	1096	patients
O	1097	1101	with
O	1102	1104	T1
O	1105	1107	or
O	1108	1110	T2
O	1111	1117	tumors
O	1118	1121	and
O	1122	1125	one
O	1126	1128	to
O	1129	1134	three
O	1135	1143	positive
O	1144	1149	nodes
O	1150	1151	(
B-outcome	1151	1153	10
I-outcome	1153	1154	-
I-outcome	1154	1158	year
I-outcome	1159	1162	LRR
I-outcome	1163	1168	rates
O	1169	1171	of
O	1172	1173	3
O	1173	1174	%
O	1175	1177	vs
O	1177	1178	.
O	1179	1181	13
O	1181	1182	%
O	1182	1183	,
O	1184	1185	p
O	1186	1187	=
O	1188	1189	0
O	1189	1190	.
O	1190	1193	003
O	1193	1194	)
O	1194	1195	.

O	1196	1208	Multivariate
O	1209	1217	analysis
O	1218	1220	of
O	1221	1224	LRR
O	1225	1228	for
O	1229	1237	patients
O	1238	1242	with
O	1243	1247	this
O	1248	1253	stage
O	1254	1256	of
O	1257	1264	disease
O	1265	1273	revealed
O	1274	1278	that
O	1279	1281	no
O	1282	1291	radiation
O	1291	1292	,
O	1293	1298	close
O	1298	1299	/
O	1299	1307	positive
O	1308	1315	margins
O	1315	1316	,
O	1317	1322	gross
O	1323	1336	extracapsular
O	1337	1346	extension
O	1346	1347	,
O	1348	1351	and
O	1352	1362	dissection
O	1363	1365	of
O	1366	1367	<
O	1367	1369	10
O	1370	1375	nodes
O	1376	1385	predicted
O	1386	1389	for
O	1390	1399	increased
O	1400	1403	LRR
O	1404	1405	(
O	1405	1411	hazard
O	1412	1418	ratios
O	1419	1420	6
O	1420	1421	.
O	1421	1423	25
O	1423	1424	,
O	1425	1426	4
O	1426	1427	.
O	1427	1429	61
O	1429	1430	,
O	1431	1432	3
O	1432	1433	.
O	1433	1435	27
O	1435	1436	,
O	1437	1440	and
O	1441	1442	2
O	1442	1443	.
O	1443	1445	66
O	1445	1446	,
O	1447	1459	respectively
O	1459	1460	)
O	1460	1461	.

O	1462	1473	Significant
B-outcome	1474	1484	predictors
I-outcome	1485	1487	of
I-outcome	1488	1491	LRR
O	1492	1495	for
O	1496	1504	patients
O	1505	1512	treated
O	1513	1517	with
O	1518	1532	postmastectomy
O	1533	1542	radiation
O	1543	1547	were
O	1548	1554	higher
O	1555	1561	number
O	1562	1565	and
O	1566	1567	>
O	1567	1569	or
O	1569	1570	=
O	1570	1572	20
O	1572	1573	%
B-outcome	1574	1582	positive
I-outcome	1583	1588	nodes
O	1588	1589	,
O	1590	1596	larger
B-outcome	1597	1602	tumor
I-outcome	1603	1607	size
O	1607	1608	,
B-outcome	1609	1623	lymphovascular
I-outcome	1624	1629	space
I-outcome	1630	1638	invasion
O	1638	1639	,
O	1640	1643	and
B-outcome	1644	1652	estrogen
I-outcome	1653	1661	receptor
I-outcome	1662	1663	(
I-outcome	1663	1665	ER
I-outcome	1665	1666	)
I-outcome	1666	1667	-
I-outcome	1667	1675	negative
I-outcome	1676	1683	disease
O	1683	1684	.

O	1685	1694	Recursive
O	1695	1707	partitioning
O	1708	1716	analysis
O	1717	1725	revealed
O	1726	1728	ER
O	1728	1729	-
O	1729	1737	negative
O	1738	1744	status
O	1745	1747	to
O	1748	1750	be
O	1751	1754	the
O	1755	1759	most
O	1760	1768	powerful
O	1769	1782	discriminator
O	1783	1785	of
O	1786	1789	LRR
O	1790	1792	in
O	1793	1803	irradiated
O	1804	1812	patients
O	1812	1813	.

O	1814	1828	Postmastectomy
O	1829	1838	radiation
O	1839	1848	decreases
O	1849	1852	LRR
O	1853	1856	for
O	1857	1865	patients
O	1866	1870	with
O	1871	1877	breast
O	1878	1884	cancer
O	1884	1885	,
O	1886	1895	including
O	1896	1901	those
O	1902	1906	with
O	1907	1912	Stage
O	1913	1915	II
O	1916	1922	breast
O	1923	1929	cancer
O	1930	1933	and
O	1934	1937	one
O	1938	1940	to
O	1941	1946	three
O	1947	1955	positive
O	1956	1961	lymph
O	1962	1967	nodes
O	1967	1968	.
